JP2010527370A - Cns疾患治療のための5−ヒドロキシトリプタミン−6リガンドとしての5−(アミノアザシクリル)−3−スルホニル−1h−インダゾール - Google Patents

Cns疾患治療のための5−ヒドロキシトリプタミン−6リガンドとしての5−(アミノアザシクリル)−3−スルホニル−1h−インダゾール Download PDF

Info

Publication number
JP2010527370A
JP2010527370A JP2010508533A JP2010508533A JP2010527370A JP 2010527370 A JP2010527370 A JP 2010527370A JP 2010508533 A JP2010508533 A JP 2010508533A JP 2010508533 A JP2010508533 A JP 2010508533A JP 2010527370 A JP2010527370 A JP 2010527370A
Authority
JP
Japan
Prior art keywords
formula
compound
group
amine
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010508533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527370A5 (enExample
Inventor
ニコラス ハイダー シモン
アンドラエ パトリック
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2010527370A publication Critical patent/JP2010527370A/ja
Publication of JP2010527370A5 publication Critical patent/JP2010527370A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010508533A 2007-05-15 2008-05-13 Cns疾患治療のための5−ヒドロキシトリプタミン−6リガンドとしての5−(アミノアザシクリル)−3−スルホニル−1h−インダゾール Withdrawn JP2010527370A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93018607P 2007-05-15 2007-05-15
PCT/US2008/063507 WO2008144299A1 (en) 2007-05-15 2008-05-13 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders

Publications (2)

Publication Number Publication Date
JP2010527370A true JP2010527370A (ja) 2010-08-12
JP2010527370A5 JP2010527370A5 (enExample) 2011-06-30

Family

ID=39618919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508533A Withdrawn JP2010527370A (ja) 2007-05-15 2008-05-13 Cns疾患治療のための5−ヒドロキシトリプタミン−6リガンドとしての5−(アミノアザシクリル)−3−スルホニル−1h−インダゾール

Country Status (9)

Country Link
US (1) US7939520B2 (enExample)
EP (1) EP2158195A1 (enExample)
JP (1) JP2010527370A (enExample)
CA (1) CA2685318A1 (enExample)
CL (1) CL2008001413A1 (enExample)
PA (1) PA8780701A1 (enExample)
PE (1) PE20090250A1 (enExample)
TW (1) TW200908962A (enExample)
WO (1) WO2008144299A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541693B (zh) 2014-07-08 2018-10-16 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
WO2004074243A2 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
WO2007032833A1 (en) 2005-08-15 2007-03-22 Wyeth Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
WO2008144299A1 (en) 2008-11-27
PE20090250A1 (es) 2009-03-08
CL2008001413A1 (es) 2008-07-04
EP2158195A1 (en) 2010-03-03
PA8780701A1 (es) 2008-12-18
TW200908962A (en) 2009-03-01
CA2685318A1 (en) 2008-11-27
US7939520B2 (en) 2011-05-10
US20080293688A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
RU2134266C1 (ru) Производные 5-арилиндола и их применение в качестве агонистов серотонина (5-нт1)
JP2614981B2 (ja) インドール、インダゾール及びベンズイソオキサゾール化合物、それらの製法およびそれらを含有する製薬組成物
JP2006517966A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルアザインドールまたは−アザインダゾール誘導体
JP4335684B2 (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのインドリルアルキルアミン誘導体
JP2008502628A5 (enExample)
JP2006518385A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルインダゾール
JP2002507611A (ja) イミダゾロン食欲抑制薬:ii.フェニル誘導体
TWI481605B (zh) 作為5-羥色胺-6配位基之1-(芳基磺醯基)-4-(哌-1-基)-1h-苯并咪唑
EP2088861A2 (en) Benzimidazole compounds
ZA200500021B (en) 1-(Aminoalkyl)-3-sylfonnylindole and -indazole derivatives as 5-hydroxytryptamine-5 ligands
JPH07506825A (ja) 5−ht1レセプターアゴニストとしての縮合イミダゾール及びトリアゾール誘導体
NZ228721A (en) Substituted indoles and indazoles and pharmaceutical compositions
EP1723105A1 (en) Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
JP2009533441A (ja) 5‐ヒドロキシトリプタミン‐6リガンドとしての置換ジヒドロ[1,4]オキサジノ[2,3,4‐hi]インダゾール誘導体
AU3895693A (en) Imidazole, triazole and tetrazole derivatives
JP2010527370A (ja) Cns疾患治療のための5−ヒドロキシトリプタミン−6リガンドとしての5−(アミノアザシクリル)−3−スルホニル−1h−インダゾール
JP2006528184A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニルジヒドロイミダゾピリジノン化合物
TW200831481A (en) Derivatives of 5-alkyloxy-indolin-2-one, their preparation and their applications in therapeutics
CA2619309A1 (en) Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
US20050107431A1 (en) Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
JP2009532471A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニル−3−ヘテロシクリルインダゾール誘導体
WO2000050420A1 (fr) Derives d'acide 7-heteroquinoxaline carboxilique 6-substitue et leurs sels d'addition, procedes de preparation de ces derives et de leurs sels d'addition
WO2007053353A2 (en) Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US5047402A (en) Cyclic amides as medicaments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110510

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110510

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130219